Homepage | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
Clinical trial outcomes for SLE: what we have and what we need
The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
05 Lifestyle for lupus patients: exercise, diet, and well-being ...
As systemic lupus erythematosus (SLE) is a chronic condition with a significant impact on physical and mental health, all potential interventions to improve quality of life are relevant for SLE patients. Among the possible non-pharmacological interventions, exercise and diet have a pivotal role.1 2 For SLE patients aerobic exercise programs …
Central nervous system infections in patients with systemic lupus ...
We aimed to conduct a systematic review and meta-analysis of studies on central nervous system (CNS) infections in patients with SLE, in order to describe their clinical and microbiological characteristics, and outcomes. A systematic search of PubMed/Medline and Embase electronic databases was performed (March 2021) to identify all published studies on CNS infections and their characteristics ...
Alopecias in lupus erythematosus | Lupus Science & Medicine
Several patterns of hair loss can occur in lupus erythematosus (LE). Alopecias which show histological characteristics of LE are LE-specific, and include discoid LE (DLE), diffuse or patchy hair loss in acute LE, subacute cutaneous LE, and rarely tumid LE. Lupus hair in SLE is a poorly characterised entity and may be a form of telogen effluvium. Alopecia areata can …
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in ...
Objective COVID-19 induces the development of autoimmune diseases, including SLE, which are characterised by inflammation, autoantibodies and thrombosis. However, the effects of COVID-19 on SLE remain unclear. Methods We investigated the effects of COVID-19 on SLE development and progression in three animal models. Plasmids encoding SARS-CoV-2 spike protein and ACE2 receptor were injected into ...
Cutaneous vasculitis in SLE | Lupus Science & Medicine
Cutaneous vasculitis was observed in 17.3% of patients with SLE. The mean time to cutaneous vasculitis after SLE diagnosis was 4.78 years (95% CI 3.96 to 5.60). Among patients who developed cutaneous vasculitis, 50% had the onset by 2 years after their SLE diagnosis and 75% by 10 years after their diagnosis.
PO.5 E- poster session 5: lupus nephritis - Lupus Science & Medicine
Purpose The effect of belimumab (BEL) on renal outcomes has been previously demonstrated in the BLISS-LN study in patients with active lupus nephritis (LN).1 Here we evaluate the effect of BEL on pre-specified extra-renal outcomes in patients with LN enrolled in the BLISS-LN study. Methods In this Phase 3, double-blind, placebo (PBO)-controlled study (GSK Study BEL114054; [NCT01639339][1 ...
Utility of skin biopsy in patients with systemic lupus erythematosus ...
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can affect multiple organs, commonly the skin in 70%–85% of patients.1 Cutaneous lupus is associated with the common typical histological finding of perivascular lymphocytic infiltration and interface dermatitis.2 While suggestive, these findings are non-specific and require clinicopathological correlation, which may be ...
Major infections in newly diagnosed systemic lupus …
Objective To evaluate the risk of major infections and the relationship between major infections and mortality in patients with newly diagnosed SLE. Methods A newly diagnosed (<3 months) hospitalised Systemic Lupus Inception Cohort (hSLIC) in our centre during 1 January 2013 and 1 November 2020 was established. All patients were followed up for at least 1 year or until death.